Takeda Revises FY2024 Financial Forecasts

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced revised financial forecasts for the fiscal year ending March 31, 2025. The updated outlook projects increased revenue and profit figures compared to earlier estimates announced in May.

Takeda has adjusted its revenue forecast to JPY 4,480 billion, a 3.0% rise, largely due to milder-than-expected generic erosion of VYVANSE in the U.S. Operating profit is also expected to increase to JPY 265 billion, marking a 17.8% jump.

Further, the company's net profit forecast increased by 17.2% to JPY 68 billion, with a projected earnings per share of JPY 43.03. The firm attributes these revisions to improved business momentum and favorable forex assumptions.